Revolution Medicines (RVMD) Expected to Announce Quarterly Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMD) is expected to be announcing its Q3 2025 results before the market opens on Wednesday, November 5th. Analysts expect the company to announce earnings of ($1.39) per share and revenue of $1.8070 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

Revolution Medicines (NASDAQ:RVMD) last released its earnings results on Wednesday, August 6th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.94) by ($0.37). Revolution Medicines’s revenue was up .0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.81) EPS. On average, analysts expect Revolution Medicines to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Revolution Medicines Stock Performance

Shares of NASDAQ:RVMD opened at $58.84 on Monday. The company has a market capitalization of $11.00 billion, a price-to-earnings ratio of -13.08 and a beta of 1.25. The firm’s 50 day simple moving average is $46.38 and its 200 day simple moving average is $41.24. The company has a debt-to-equity ratio of 0.13, a current ratio of 11.79 and a quick ratio of 11.79. Revolution Medicines has a fifty-two week low of $29.17 and a fifty-two week high of $62.40.

Insider Activity

In other Revolution Medicines news, insider Mark A. Goldsmith sold 13,411 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The shares were sold at an average price of $45.82, for a total transaction of $614,492.02. Following the sale, the insider directly owned 452,309 shares in the company, valued at approximately $20,724,798.38. This trade represents a 2.88% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Jack Anders sold 2,320 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $45.82, for a total transaction of $106,302.40. Following the sale, the chief financial officer owned 110,994 shares in the company, valued at $5,085,745.08. This trade represents a 2.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 188,033 shares of company stock worth $8,456,208. Corporate insiders own 8.20% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. boosted its holdings in Revolution Medicines by 41.7% during the second quarter. Osaic Holdings Inc. now owns 3,487 shares of the company’s stock worth $128,000 after purchasing an additional 1,027 shares during the last quarter. Hudson Bay Capital Management LP acquired a new position in Revolution Medicines during the second quarter worth $1,124,000. CANADA LIFE ASSURANCE Co boosted its holdings in Revolution Medicines by 14.4% during the second quarter. CANADA LIFE ASSURANCE Co now owns 34,766 shares of the company’s stock worth $1,282,000 after purchasing an additional 4,386 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Revolution Medicines by 592.2% during the second quarter. Tower Research Capital LLC TRC now owns 71,534 shares of the company’s stock worth $2,632,000 after purchasing an additional 61,199 shares during the last quarter. Finally, E Fund Management Co. Ltd. boosted its holdings in Revolution Medicines by 11.8% during the second quarter. E Fund Management Co. Ltd. now owns 17,075 shares of the company’s stock worth $628,000 after purchasing an additional 1,802 shares during the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on RVMD. The Goldman Sachs Group increased their price target on shares of Revolution Medicines from $65.00 to $73.00 and gave the company a “buy” rating in a research report on Friday, September 12th. National Bankshares set a $80.00 price target on shares of Revolution Medicines in a research report on Friday, October 17th. Wells Fargo & Company increased their price target on shares of Revolution Medicines from $67.00 to $70.00 and gave the company an “overweight” rating in a research report on Thursday, September 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Wednesday, October 8th. Finally, Needham & Company LLC increased their price target on shares of Revolution Medicines from $56.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, September 11th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus price target of $77.50.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.